Moleculin Announces Reverse Stock Split
HOUSTON, March 19, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced a 1-for-15...
Moleculin to Present at the 36th Annual ROTH Conference
Live webcast fireside chat on Monday, March 18th at 9:00 AM PT HOUSTON, March 12, 2024 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat...
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
- MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment - MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54% (N=13) - First 1st line...
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
HOUSTON, Dec. 20, 2023 -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a...
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
- CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with Annamycin (n=9) - Durability of CR's up to 8 months & climbing (no relapses to date) - Recruitment in MB-106 Phase 1B/2 clinical trial reaches 59%...
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
- MB-106: CR rate of 38% (N=8) with durability up to 8 months - Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) - MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) - MB-107 Phase 1B/2...
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
- MB-106: CR rate of 38% (N=8) with durability up to 8 months - Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) - MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) - MB-107 Phase 1B/2...
Moleculin Reports Third Quarter 2023 Financial Results
- Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 - Third quarter marked by additional positive clinical data from Annamycin lead development programs - Growing body of Annamycin efficacy and safety clinical data expected to...
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
HOUSTON, Nov. 7, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will...
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
- Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting - Annamycin continues to be 100% non-cardiotoxic - Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma HOUSTON, Nov. 6,...